Welcome to our dedicated page for BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund news (Ticker: DCF), a resource for investors and traders seeking the latest updates and insights on BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund's position in the market.
On November 1, 2022, BNY Mellon completed the sale of Alcentra NY to Franklin Templeton. This transaction led to new sub-investment advisory agreements for the BNY Mellon High Yield Strategies Fund and BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc. Alcentra NY is now the sub-adviser under these agreements. While shareholder approval is pending for the BNY Mellon Alcentra Global Multi-Strategy Credit Fund, an interim advisory agreement has been approved to manage investments. BNY Mellon Investment Management oversees $1.8 trillion in assets.
FAQ
What is the current stock price of BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund (DCF)?